Stockreport

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Ka Break...

BridgeBio Oncology Therapeutics, Inc.  (BBOT) 
PDF Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Ka and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust monothe [Read more]